NCT00216294View on ClinicalTrials.gov

Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions
Obsessive Compulsive Disorder (OCD)
Interventions
DRUG

RG1068 (Synthetic Human Secretin)

Trial Locations (1)

46222

LaRue Carter Hospital, Indianapolis

All Listed Sponsors
collaborator

Shekhar, Anantha M.D., Ph.D.

INDIV

collaborator

Repligen Corporation

INDUSTRY

lead

Indiana University School of Medicine

OTHER

NCT00216294 - Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder | Biotech Hunter | Biotech Hunter